Disclosures: Ai-Thien Do: Nothing to Disclose, Ming-Lung Yu: Abbvie, Gilead and Roche diagnostics.: Grant/Research Support, Abbott, Abbvie, Gilead, Roche and Roche diagnostics: Consultant, Abbvie, BMS, Gilead, Roche and Roche diagnostics: Speaking and Teaching, Hidenori Toyoda: Nothing to Disclose, Seng Gee Lim: Nothing to Disclose, Ramsey Cheung: Nothing to Disclose, Man-Fung Yuen: Nothing to Disclose, Yasuhito Tanaka: Nothing to Disclose, Wan Long Chuang: Gilead: Speaking and Teaching, AbbVie: Speaking and Teaching, BMS: Speaking and Teaching, Vaccitech: Consultant, PharmaEssentia: Consultant, Chao Wu: Nothing to Disclose, Maria Buti: Nothing to Disclose, Nothing to Disclose, Adrian Gadano: Nothing to Disclose, Ming-Lun Yeh: Nothing to Disclose, Chung-Feng Huang: Nothing to Disclose, Rui Huang: Nothing to Disclose, Jee-Fu Huang: Nothing to Disclose, Chia-Yen Dai: Nothing to Disclose, Mayumi Maeda: Nothing to Disclose, Kaori Inoue: Nothing to Disclose, Chul-Jin Lee: Nothing to Disclose, Cheng-Hao Tseng: Nothing to Disclose, Ana Barreira: Nothing to Disclose, Rex Wan-Hin Hui: Nothing to Disclose, Kwan-Lung Ko: Nothing to Disclose, Yoko Yoshimaru: Nothing to Disclose, Takanori Suzuki: Nothing to Disclose, Irina Sandra: Nothing to Disclose, Raluca Marin: Nothing to Disclose, Vy Nguyen: Nothing to Disclose, Yao-Chun Hsu: Gilead Sciences: Grant/Research Support, Gilead Sciences: Advisor, Sysmex: Advisor, Abbvie: Speaking and Teaching, Bristol Myers Squibb: Speaking and Teaching, Gilead Sciences: Speaking and Teaching, Roch: Speaking and Teaching, Huy Trinh: Nothing to Disclose, Jiayi Li: Nothing to Disclose, jianqing zhang: Nothing to Disclose, Eiichi Ogawa: Gilead Sciences: Grant/Research Support, Dong Hyun Lee: Nothing to Disclose, Takanori Ito: Chugai Pharmaceutical Co., Ltd.: Grant/Research Support, Chugai Pharmaceutical Co., Ltd
It communicates with multiple organs, including the brain, pancreas, stomach, and digestive system to help regulate hunger, blood sugar, and energy balance
Compare these modest outcomes to the first month results on semaglutide , where users commonly report 4-8 pounds of weight loss alongside significant appetite suppression
Controlling the global obesity epidemic
Here is an option that's not more effective
"So if you do start at a higher level, you can really get to a more healthy state, which is everyone's goal, I think." Beyond Lilly and Novo
